Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Travoprost is a synthetic prostaglandin F2α analog and an ester prodrug used as an ophthalmic solution to lower elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. After administration as eye drops, it is absorbed through the cornea and hydrolyzed to its active free acid form. The active metabolite acts as a selective agonist at the prostaglandin F receptor (FP) in the eye, increasing aqueous humor outflow via both uveoscleral and trabecular meshwork pathways. This mechanism reduces intraocular pressure and helps prevent optic nerve damage associated with glaucoma. Travoprost is considered highly selective for its target receptor compared to other agents in its class[1][2][3][5][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on travoprost.